Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCORI To Solicit More Head-To-Head Comparative Studies

Executive Summary

The Patient-Centered Outcomes Research Institute announces plans to encourage the submission of more proposals for head-to-head clinical comparative effectiveness studies. Among the research topics the institute will encourage are the Institute of Medicine’s top 100 priorities and recommendations from America’s Health Insurance Plans.

You may also be interested in...



Hepatitis C Drug Head-To-Head Comparative Studies Debated At PCORI Workshop

There appeared to be support for the idea that if head-to-head studies are funded, they should focus on “high risk populations,” such as intravenous drug users.

To Get The Most Out Of Health CER, Hire A Mathematician, Conferees Say

Economists, mathematicians and behavioral scientists are among the non-health care specialists who could be essential to ensuring the wealth of comparative effectiveness research data available is used to its full potential, according to speakers at a recent CER event.

PCORI’s Selby Expects More Drug-Related Comparative Research In 2014

Research involving drugs has been limited since the Patient-Centered Outcomes Research Institute began project funding, but institute Executive Director Joe Selby expects that to change as PCORI prepares to issue funding announcements for pragmatic trials.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS055767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel